Mahajan Imaging & Labs introduces Alzheimer’s diagnostics with AI-integrated testing

image credit- freepik

Mahajan Imaging & Labs, a leading chain of advanced diagnostic centres in India, has expanded its Alzheimer’s diagnostic capabilities with the introduction of an artificial intelligence (AI)-integrated blood biomarker test, supported by a structured PET and MRI imaging pathway, offered under its Dementia Diagnostic Series, which includes Alzheimer’s blood biomarker testing using the pTAU217/βAmyloid1-42 ratio along with cognitive health and genetic risk panels, AI-enabled MRI brain imaging with dementia protocol, and FDG PET imaging where clinically indicated.

The new pTAU/Aβ1-42 blood biomarker test, which is USFDA- and CDSCO-approved, enables the detection of Alzheimer’s-related biological changes well before severe cognitive symptoms become evident, supporting a shift from symptom-led assessment to a biology-first diagnosis in Indian clinical practice.

Recent estimates indicate that over 8.8 million Indians aged 60 and above are living with dementia, with Alzheimer’s disease accounting for the majority of cases. This number is projected to nearly double over the next decade, highlighting the growing need for early and accurate diagnostic tools that support timely intervention and care planning. 

Until recently, Alzheimer’s biomarker testing relied on cerebrospinal fluid samples, which meant a more invasive procedure for patients. Today, with plasma-based testing, we can obtain the same critical information through a simple blood test. This makes diagnosis easier, safer, and far more acceptable for patients. Mahajan Imaging & Labs now performs the pTAU/Aβ1-42 blood biomarker test in its Reference Laboratory, enabling faster reporting, closer clinical integration with imaging findings, and improved affordability for both patients and clinicians. 

Globally, Alzheimer’s diagnosis increasingly depends on amyloid PET imaging and cerebrospinal fluid (CSF) testing. Commenting on the Alzheimer’s diagnostics scenario in India, Dr. Harsh Mahajan, Padma Shri Awardee, Founder & Chairman of Mahajan Imaging & Labs, said, “In India, limited availability and high costs, as much as Rupees two lakhs per scan, have restricted widespread access to amyloid PET, leaving many clinicians dependent on symptom-based assessments. A key differentiator of Mahajan Imaging & Labs’ approach is the integration of laboratory diagnostics with imaging. The combination of blood biomarkers with 18F FDG can be a game-changer not only in early diagnosis of Alzheimer’s, but also in follow-up of patients on the new treatments to assess for treatment response. The conclusions of this symposium shall be sent to the Neurological Society of India to help in formulating guidelines for the diagnosis and treatment of Alzheimer’s in India. This may even have implications on the approach to early diagnosis of Alzheimer’s in other parts of the world.”